+ All Categories

Home > Documents > SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or...

SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or...

Date post:	22-Jun-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Download Report this document

Share this document with a friend

Embed Size (px):

12

SABCS 2019

Transcript

Page 1: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 2: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 3: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 4: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 5: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 6: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 7: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 8: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 9: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 10: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 11: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Page 12: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

SABCS 2019

Recommended

Androgyne Tonique2 - Placebo City · 2010-07-17 · Androgyne Tonique2 - Placebo City

PRACTICE CHANGING STUDIES IN GASTROINTESTINAL … · safety, PK, QoL Treatment arm A Treatment arm B Trastuzumab + pertuzumab 840 mg IV q3w Trastuzumab + placebo IV q3w • Geographical

Tu esti placebo esti placebo...Title Tu esti placebo Author Joe Dispenza Keywords Tu esti placebo - Joe Dispenza Created Date 2/27/2019 1:20:32 PM

Presentazione standard di PowerPoint - Acute medicine€¦ · •Interventional radiology (mechanical fragmentation, thrombosuction) ... Comparator drug Placebo Placebo Warfarin Placebo

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive ...

IQWiG Reports – Commission No. A13-10 Pertuzumab – Benefit ...€¦ · Extract of dossier assessment A13-10 Version 1.0 Pertuzumab – Benefit assessment acc. to § 35a Social

Placebo Effect .

FDA Approval Summary: Pertuzumab for adjuvant treatment …...placebo 3.7%). Almost all diarrhea serious adverse events (SAEs) required hospitalization (56 patients in the pertuzumab

Placebo welcome edition

Pertuzumab in combination with trastuzumab and docetaxel ...

PowerPoint Presentation · Primary Endpoint: Responder-HMB Reduction Q4:19/Q2:20. Placebo + placebo add -back. 100 mg + placebo add -back. 100 mg + add -back. 200 mg + placebo add

125409Orig1s000 · evaluating the safety and efficacy of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic

pan-Canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab … · CLEOPATRA was an industry-funded multicentre, double-blind, placebo-controlled randomized controlled

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment ...